Enhancing anti-tumor response in melanoma cells with defective sting signaling

Inventors

Mulé, James • Falahat, Rana • Barber, Glen

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Assignees

Moffitt Cancer Center

Member
University of Miami
University of Miami

The University of Miami, established in 1925 and based in Coral Gables, Florida, is a private research university recognized for its comprehensive academic offerings, robust research infrastructure, and strong interdisciplinary focus. Home to more than 19,000 students and with more than 400 acres of campuses across the Miami region, its mission encompasses education, research, innovation, and community service. The institution supports clinical, biomedical, marine, and atmospheric research initiatives, delivers diverse undergraduate and graduate programs, and maintains numerous research centers and institutes dedicated to scientific, medical, and societal advancements.

Publication Number

US-12599621-B2

Patent

Publication Date

2026-04-14

Expiration Date


Abstract

Disclosed herein is a method for enhancing antitumor T cell responses in subjects. The method involves administering to the subject in need thereof a composition comprising a demethylating agent in an amount effective to demethylate STING proteins in the tumor cells. This method is particularly useful in subjects with deficient STING expression in the tumor cells. Therefore, also disclosed is a method for treating a tumor in a subject that involves detecting in a biopsy sample from the subject reduced STING expression, reduced cGAS expression, or a combination thereof; and then administering to the subject a demethylating agent in an amount effective to demethylate STING proteins in the tumor cells. The method can further involve administering to the subject a therapeutically effective amount of a STING agonist. The method can further involve administering to the subject tumor infiltrating lymphocytes (TILs), such as HLA-matched TILs.

Core Innovation

The disclosure relates to immunotherapies for treating melanoma and other solid tumors by targeting reduced STING/cGAS pathway signaling. Many human melanoma cell lines lack or have defective STING/cGAS signaling, linked to reduced STING expression and/or reduced cGAS expression and/or elevated DNA methylation within regulatory regions of STING and/or cGAS genes.

A subject is selected by detecting in a biopsy sample reduced STING expression, reduced cGAS expression, a combination thereof, and/or elevated DNA methylation within regulatory regions of STING and/or cGAS genes. A demethylating agent is then administered, with co-administration of a STING agonist also described, as a way to restore STING/cGAS expression and downstream signaling.

The disclosure states that demethylating treatment partially restores STING/cGAS expression and associated CXCL10 and IFN-β induction. It further states that stimulation of STING-intact melanoma cells with a STING agonist increases CXCL10 and IFN-β induction, upregulates MHC class I (HLA-A,B,C), and enhances HLA-matched TIL IFN-γ release and cytotoxicity, with STING activation associated with downstream chemokine-driven T-cell recruitment and improved TIL trafficking/expansion in adoptive cell transfer contexts.

Claims Coverage

Independent claim clm-00001 is directed to a treatment method and includes two core inventive steps: subject selection based on STING/cGAS biomarkers in a biopsy sample and co-administration of a STING agonist with a demethylating agent. No other independent claims are provided in the provided partial content.

Biomarker-detected selection of subjects for STING/cGAS targeting

Detecting in a biopsy sample from the subject reduced STING expression, reduced cGAS expression, or a combination thereof and/or elevated DNA methylation within regulatory regions of STING and/or cGAS genes.

Co-administration of a STING agonist with a demethylating agent

Co-administering to the subject a therapeutically effective amount of a STING agonist and a demethylating agent.

The claim coverage centers on matching subjects based on reduced STING/cGAS expression and/or elevated DNA methylation in regulatory regions, and treating by co-administering a STING agonist together with a demethylating agent.

Stated Advantages

Partially restores STING/cGAS expression and associated CXCL10 and IFN-β induction.

Increases CXCL10 and IFN-β induction and upregulates MHC class I (HLA-A,B,C).

Enhances HLA-matched TIL IFN-γ release and cytotoxicity.

Links STING activation to downstream chemokine-driven T-cell recruitment (CXCL10/CXCL9) and improved TIL trafficking/expansion in adoptive cell transfer contexts.

Documented Applications

Treating melanoma, ovarian cancer, breast cancer, or colorectal cancer in a subject using the claimed biopsy-based detection and co-administration regimen.

HLA-matched TIL adoptive cell transfer contexts, where STING activation is linked to improved TIL trafficking/expansion and enhanced TIL function.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.